BioLife Solutions (BLFS)

The company is best known for its biopreservation media, including CryoStor and HypoThermosol, which are designed to protect cells and tissues during low-temperature storage and transport. These products form a key part of BioLife’s cell processing offering and support customers that need consistent quality controls across research, clinical development, and commercial manufacturing workflows. BioLife also provides tools and systems for controlled-rate freezing, thawing, cold chain logistics, and related bioproduction processes.

BioLife serves a market shaped by the growth of advanced therapies, where supply chains are complex and failures can be costly because many treatments are highly personalized or time-sensitive. Its solutions are intended to reduce manufacturing risk, improve reproducibility, and support compliance with regulated biopharmaceutical standards.

The company generates most of its revenue in the United States, although its customer base is tied to a global biotechnology and pharmaceutical ecosystem. As a listed company, BioLife’s performance is influenced by adoption of cell and gene therapy platforms, customer clinical and commercial progress, capital spending in biomanufacturing, and demand for specialized cold chain infrastructure.